Status:
COMPLETED
Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program
Lead Sponsor:
Lady Davis Institute
Conditions:
Scleroderma
Scleroderma, Systemic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Contagious disease outbreaks, such as the coronavirus disease 2019 (COVID-19) outbreak, and associated restrictions to prevent spread can lead to negative psychological outcomes, including loneliness,...
Detailed Description
Background: Social distancing and movement restrictions during contagious disease outbreaks are necessary to reduce spread but can lead to negative social and psychological outcomes, including lonelin...
Eligibility Criteria
Inclusion
- Classified as having SSc by a physician
- PROMIS Anxiety 4a v1.0 T-score greater than or equal to 55
- Have regular, reliable internet access
- Be fluent in English or French
Exclusion
- Receiving counseling or therapy currently
- Having a positive test for the COVID-19 virus
Key Trial Info
Start Date :
April 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 24 2020
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT04335279
Start Date
April 9 2020
End Date
July 24 2020
Last Update
February 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir Mortimer B. Davis Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2